Michael A Renzi

20030130197, Jul 10, 2003

May 23, 2001

09/863600

Michael Renzi - Harleysville PA, US
Carlos Plata-Salaman - Ambler PA, US
Linda Jolliffe - Hillsborough PA, US
Francis Farrell - Doylestown PA, US
Dana Johnson - Upper Black Eddy PA, US

A61K038/08

514/015000, 514/016000

Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

20040209812, Oct 21, 2004

Mar 26, 2004

10/810755

Michael Renzi - Pipersville PA, US
Michael Gold - Newton PA, US
Kenneth Rhodes - Hillsborough NJ, US
Navneeth Thirumalai - Kendall Park NJ, US
Francis Farrell - Doylestown PA, US
Linda Jolliffe - Belle Mead NJ, US

A61K038/18

514/012000

The present invention demonstrates EPO's efficacy in promoting patient recovery following an ischemic event. The invention demonstrates that a longer window of opportunity exists for the initial uses of EPO in treating ischemic stroke than had been previously been understood.

20070065885, Mar 22, 2007

Sep 8, 2006

11/530234

Michael Renzi - Harleysville PA, US
Navneeth Thirumalai - Kendall Park NJ, US
Linda Jolliffe - Hillsborough NJ, US
Francis Farrell - Doylestown PA, US

G01N 33/567
G01N 33/53

435007200

The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.

20090170759, Jul 2, 2009

Jul 11, 2007

11/776003

Michael Renzi - Harleysville PA, US
Carlos Plata-Salaman - Ambler PA, US
Linda Jolliffe - Hillsborough NJ, US
Francis Farrell - Doylestown PA, US
Dana Johnson - Upper Black Eddy PA, US

A61K 38/16
A61K 38/10
A61K 38/08
C12N 5/06

514 12, 514 13, 514 14, 514 15, 514 16, 435325

Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.